From victim to ally: the kidney as an emerging target for the treatment of diabetes mellitus
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Elevated glucose blood levels are the key criteria for diagnosing diabetes mellitus (DM). Hyperglycaemia contributes to the pathophysiology associated with DM, including microvascular and possibly macrovascular disease. In spite of a wide range of pharmacological options available to reduce hyperglycaemia in DM, epidemiological studies suggest that glucose levels remain high in a substantial proportion of patients. This supports the need for additional strategies for the treatment of hyperglycaemia. SCOPE: This review focuses on the role of the kidney in glucose reabsorption and explores inhibition of renal glucose reabsorption as a novel approach to treat type 2 DM. A literature search to August 2008 using PubMed was used to compile data for review. Abstracts and presentations from the American Diabetes Association and the European Association for the Study of Diabetes, the American Society of Nephrology, and the International Society of Nephrology Annual Meetings were also searched for relevant studies. FINDINGS: Glucose filtered by the kidney is normally reabsorbed into the proximal renal tubule. Data from animal models suggest that approximately 90% of this reabsorption occurs through the sodium-coupled glucose cotransporter (SGLT) 2, which is a protein expressed almost exclusively in the proximal tubule of the kidney. Inhibition of SGLT2, and thus inhibition of renal glucose reabsorption, has the potential to reduce hyperglycaemia in patients with DM. Patients with familial renal glucosuria, a genetic disorder of SGLT2, do not appear to have adverse clinical consequences related to impaired renal reabsorption of glucose, which suggests that SGLT2 might be both an effective and safe treatment target for hyperglycaemia. In animal models of DM, pharmaceutical inhibition of SGLT2 reduces hyperglycaemia, and may improve insulin resistance. CONCLUSION: Reduction of renal glucose reabsorption is a novel approach to DM treatment that potentially provides improvements in glucose lowering. Various SGLT2 inhibitors are currently in development in human trials.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Relative or absolute deficiency of insulin and/or glucose promotes preferential metabolism of fats/triglycerides into glycerol and 3 fatty acids (via activation of adipocyte hormone sensitive lipase).”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [108]
In the citing paper
“Increased free fatty acid delivery to the liver (mitochondrial oxidation) generates ketones (e.g., acetone, acetoacetone, and beta-hydroxybutyrate).”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [108]
In the citing paper
“Mild ketosis due to carbohydrate restricted dietary ketosis may have favorable health effects (i.e., decreased hunger; treatment of epilepsy; fatty acids are the main fuel for the heart, which has little glycogen)”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [108]
In the citing paper
“SGLT-2 inhibitors contribute to lower glucose levels, promote negative caloric balance, but do not increase insulin secretion”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [108]
In the citing paper
“Along with fasting, starvation, carbohydrate restricted diets, and poorly controlled type 1 diabetes mellitus, SGLT-2 inhibitors are associated with ketonemia”
From Anti-Obesity Medications and Investigational Agents: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022 (2022) · cites this paper as [108]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 8×
“2009 Informa UK - Curr Med Res Opin 2009; 25(3) The kidney as a target in treating diabetes Bays 675”
BackgroundInfluentialIntensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Ohkubo, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N., & Shichiri, M. (1995) · Diabetes Research and Clinical Practice · doi:10.1016/0168-8227(95)01064-k · Cited by 3,079
Islet cell failure in type 2 diabetes
Prentki, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29103 · Cited by 1,690
Ehrenkranz, J. R. L., Lewis, N. G., Ronald Kahn, C., & Roth, J. (2005) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.532 · Cited by 930
Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins
Wood, I. S., & Trayhurn, P. (2003) · British Journal of Nutrition · doi:10.1079/bjn2002763 · Cited by 889
Hyperglycemie and Microvascular and Macrovascular Disease in Diabetes
Klein, R. (1995) · Diabetes Care · doi:10.2337/diacare.18.2.258 · Cited by 845
Rossetti, L., Smith, D., Shulman, G. I., Papachristou, D., & DeFronzo, R. A. (1987) · Journal of Clinical Investigation · doi:10.1172/jci112981 · Cited by 809
Rahmoune, H., Thompson, P. W., Ward, J. M., Smith, C. D., Hong, G., & Brown, J. (2005) · Diabetes · doi:10.2337/diabetes.54.12.3427 · Cited by 777
Meng, W., Ellsworth, B. A., Nirschl, A. A., McCann, P. J., Patel, M., Girotra, R. N., Wu, G., Sher, P. M., Morrison, E. P., Biller, S. A., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm701272q · Cited by 634
Active sugar transport in health and disease
Wright, E. M., Hirayama, B. A., & Loo, D. F. (2007) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2006.01746.x · Cited by 627
Paget's Disease of the Mandible
Patel, M. B., & Bhalla, A. (2008) · New England Journal of Medicine · doi:10.1056/nejmicm066227 · Cited by 610
Gerich, J. E., Meyer, C., Woerle, H. J., & Stumvoll, M. (2001) · Diabetes Care · doi:10.2337/diacare.24.2.382 · Cited by 606
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure
Nesto, R. W., Bell, D., Bonow, R. O., Fonseca, V., Grundy, S. M., Horton, E. S., Le Winter, M., Porte, D., Semenkovich, C. F., Smith, S., et al. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.256 · Cited by 585
Renal Na+-glucose cotransporters
Wright, E. M. (2001) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.2001.280.1.f10 · Cited by 583
Brenner and Rector's The Kidney
Bazilinski, N. G. (2000) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.284.1.100 · Cited by 577
The sodium/glucose cotransport family SLC5
Wright, E. M., & Turk, E. (2004) · Pfl�gers Archiv European Journal of Physiology · doi:10.1007/s00424-003-1202-0 · Cited by 537
Is Glycemic Control Improving in U.S. Adults?
Hoerger, T. J., Segel, J. E., Gregg, E. W., & Saaddine, J. B. (2008) · Diabetes Care · doi:10.2337/dc07-1572 · Cited by 477
Molecular physiology of sodium-glucose cotransporters.
Hediger, M. A., & Rhoads, D. B. (1994) · Physiological Reviews · doi:10.1152/physrev.1994.74.4.993 · Cited by 417
Komoroski, B., Vachharajani, N., Feng, Y., Li, L., Kornhauser, D., & Pfister, M. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2008.250 · Cited by 396
Molecular Analysis of the SGLT2 Gene in Patients with Renal Glucosuria
Santer, R., Kinner, M., Lassen, C. L., Schneppenheim, R., Eggert, P., Bald, M., Brodehl, J., Daschner, M., Ehrich, J. H. H., Kemper, M., et al. (2003) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000092790.89332.d2 · Cited by 305
Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus.
Meyer, C., Stumvoll, M., Nadkarni, V, Dostou, J., Mitrakou, A., & Gerich, J. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2415 · Cited by 300
Role of human liver, kidney, and skeletal muscle in postprandial glucose homeostasis
Meyer, C., Dostou, J. M., Welle, S. L., & Gerich, J. E. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00032.2001 · Cited by 269
Oku, A., Ueta, K., Arakawa, K., Ishihara, T., Nawano, M., Kuronuma, Y., Matsumoto, M., Saito, A., Tsujihara, K., Anai, M., et al. (1999) · Diabetes · doi:10.2337/diabetes.48.9.1794 · Cited by 254
Insulin resistance, the insulin resistance syndrome, and cardiovascular disease.
Reaven, G. M. (2005) · PubMed · Cited by 239
“Sick Fat,” Metabolic Disease, and Atherosclerosis
Bays, H. E. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.10.015 · Cited by 236
Self-citationGlucose transporters: Structure, function and consequences of deficiency
Brown, G. K. (2000) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1005632012591 · Cited by 224
Mogensen, C. E. (1971) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365517109090668 · Cited by 221
Grant, R., Adams, A. S., Trinacty, C. M., Zhang, F., Kleinman, K., Soumerai, S. B., Meigs, J. B., & Ross-Degnan, D. (2007) · Diabetes Care · doi:10.2337/dc06-2170 · Cited by 218
Glucotoxicity and β-Cell Failure in Type 2 Diabetes Mellitus
Kaiser, Ν., Leibowitz, G., & Nesher, R. (2003) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2003.16.1.5 · Cited by 210
Tazawa, S., Yamato, T., Fujikura, H., Hiratochi, M., Itoh, F., Tomae, M., Takemura, Y., Maruyama, H., Sugiyama, T., Wakamatsu, A., et al. (2005) · Life Sciences · doi:10.1016/j.lfs.2004.10.016 · Cited by 203
Guisasola, F. Á., Povedano, S. T., Krishnarajah, G., Lyu, R., Mavros, P., & Yin, D. (2008) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00882.x · Cited by 192
Regulatory mechanisms of Na + /glucose cotransporters in renal proximal tubule cells
Lee, Y. J., Lee, Y. J., & Han, H. J. (2007) · Kidney International · doi:10.1038/sj.ki.5002383 · Cited by 179
Hyperglycemia and Insulin Resistance: Possible Mechanisms
TOMÁS, E., LIN, Y., DAGHER, Z., SAHA, A., LUO, Z., IDO, Y., & RUDERMAN, N. B. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04262.x · Cited by 176
Bodyweight Changes Associated with Antihyperglycaemic Agents in Type 2 Diabetes Mellitus
Hermansen, K., & Mortensen, L. S. (2007) · Drug Safety · doi:10.2165/00002018-200730120-00005 · Cited by 174
Kahn, B. B., Shulman, G. I., DeFronzo, R. A., Cushman, S. W., & Rossetti, L. (1991) · Journal of Clinical Investigation · doi:10.1172/jci115031 · Cited by 171
Fox, K. M., Gerber, R. A., Bolinder, B., Chen, J., & Kumar, S. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.03.005 · Cited by 154
Clinical inertia in the management of Type 2 diabetes metabolic risk factors
Grant, R. W., Cagliero, E., Dubey, A. K., Gildesgame, C., Chueh, H. C., Barry, M. J., Singer, D. E., Nathan, D. M., & Meigs, J. B. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01095.x · Cited by 153
Type 2 Diabetes, Insulin Secretion and β-Cell Mass
Ahren, B. (2005) · Current Molecular Medicine · doi:10.2174/1566524053766004 · Cited by 143
GLUCOSE-GALACTOSE MALABSORPTION
Lindquist, B., Mbeuwisse, G., & Melin, K. (1962) · The Lancet · doi:10.1016/s0140-6736(62)92582-5 · Cited by 126
Long-term outcome of renal glucosuria type 0: the original patient and his natural history
Scholl-Burgi, S., Santer, R., & Ehrich, J. H. H. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh366 · Cited by 104
Goudswaard, A. N., Furlong, N. J., Valk, G. D., Stolk, R. P., & Rutten, G. E. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003418.pub2 · Cited by 103
Tsujihara, K., Hongu, M., SAITO, K., Inamasu, M., ARAKAWA, K., Oku, A., & MATSUMOTO, M. (1996) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.44.1174 · Cited by 96
Sodium-glucose cotransporter inhibitors for diabetes.
Isaji, M. (2007) · PubMed · Cited by 87
Metabolic and Glucosuria Studies on Naringin and Phloridzin
Booth, A. N., Jones, F. T., DeEds, F., ROBBINS, D. J., & Kupferer, B. (1958) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)64749-0 · Cited by 63
Blondel, O., Bailbé, D., & Portha, B. (1990) · Metabolism · doi:10.1016/0026-0495(90)90120-2 · Cited by 60
Suh, D., Kim, C., Choi, I., & Plauschinat, C. A. (2008) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2007.01563.x · Cited by 49
Phloretin - an uncoupler and an inhibitor of mitochondrial oxidative phosphorylation
Jonge, P. C. D., Wieringa, T., van Putten, J. P. M., Michiel, H., Krans, J. M., & DAM, K. V. (1983) · Biochimica et Biophysica Acta (BBA) - Bioenergetics · doi:10.1016/0005-2728(83)90177-9 · Cited by 42
Simonson, G. D., & Kendall, D. M. (2005) · Coronary Artery Disease · doi:10.1097/00019501-200512000-00002 · Cited by 38
Kosachunhanun, N., Benjasuratwong, Y., Mongkolsomlit, S., Rawdaree, P., Plengvidhya, N., Leelawatana, R., Bunnag, P., Pratipanawatr, T., Krittiyawong, S., Suwanwalaikorn, S., et al. (2006) · PubMed · Cited by 37
Effects of phlorizin and acipimox on insulin resistance in STZ-diabetic rats
Kim, Y. W., Kim, J. Y., & Lee, S. K. (1995) · Journal of Korean Medical Science · doi:10.3346/jkms.1995.10.1.24 · Cited by 12
Research works printed but not linked: 9
- Kosachunhanun N, 2006, J Med Assoc Thai, 89, S66
- Reaven GM, 2005, Panminerva Med, 47, 201
- Tsujihara K, 1996, I. Synthesis and pharmacological properties of 4'-dehydroxyphlorizin derivatives based on a new concept. Chem Pharm Bull (Tokyo), 44, 1174
- Isaji M, 2007, Curr Opin Investig Drugs, 8, 285
- Glombik H, 2004, Chem Abstr, 140
- Washburn W, 2003, Chem Abstr, 138
- Komoroski B, 2009, Clin Pharmacol Ther
- Leslie B, 2008, American Society of Nephrology Renal Week
- Goudswaard AN, 2004, Cochrane Database Syst Rev
Cited by
Ten things to know about ten cardiovascular disease risk factors
Bays, H. E., Taub, P. R., Epstein, E., Michos, E. D., Ferraro, R. A., Bailey, A. L., Kelli, H. M., Ferdinand, K. C., Echols, M. R., Weintraub, H., et al. (2021) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2021.100149 · Cited by 274
Self-citationSha, S., Polidori, D., Heise, T., Natarajan, J., Farrell, K., Wang, S. ‐., Sica, D., Rothenberg, P., & Plum‐Mörschel, L. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12322 · Cited by 249
Schork, A., Saynisch, J., Vosseler, A., Jaghutriz, B. A., Heyne, N., Peter, A., Häring, H.-U., Stefan, N., Fritsche, A., & Artunc, F. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0852-y · Cited by 227
Devineni, D., Morrow, L., Hompesch, M., Skee, D., Vandebosch, A., Murphy, J., Ways, K., & Schwartz, S. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01558.x · Cited by 220
Renal glucose reabsorption inhibitors to treat diabetes
Bailey, C. J. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.11.011 · Cited by 217
Metadata
- Authors
- Bays, H.
- Affiliations
- Louisville Metabolic and Atherosclerosis Research Center (US)
- Corresponding author
- Bays, Harold
- ORCID
- Bays, Harold
- Venue
- Current Medical Research and Opinion
- Publisher
- Informa UK Limited
- Published
- 2009-01-28
- Volume
- 25
- Issue
- 3
- Pages
- 671-681
- ISSN
- 0300-7995 (ISSN-L)
- 1473-4877
- OpenAlex
- W2154020052
- Cited by
- 83
- References
- 56
- Citations by year
- 2026: 3 · 2024: 5 · 2023: 5 · 2022: 7 · 2021: 4 · 2020: 5 · 2019: 2 · 2018: 2 · 2017: 9 · 2016: 5 · 2015: 9 · 2014: 7 · 2013: 5 · 2012: 5
- FWCI
- 0.66
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Current Medical Research and Opinion (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- SGLT2 inhibitors, type 2 diabetes, renal glucose reabsorption, hyperglycemia, proximal tubule, insulin resistance, glucose-lowering therapy
- MeSH terms
- Diabetes Mellitus, Glucose, Humans, Kidney, Monosaccharide Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.